CN109641908A - 五元杂环并[3,4-d]哒嗪酮类化合物、其制备方法、药物组合物及其应用 - Google Patents

五元杂环并[3,4-d]哒嗪酮类化合物、其制备方法、药物组合物及其应用 Download PDF

Info

Publication number
CN109641908A
CN109641908A CN201780032658.2A CN201780032658A CN109641908A CN 109641908 A CN109641908 A CN 109641908A CN 201780032658 A CN201780032658 A CN 201780032658A CN 109641908 A CN109641908 A CN 109641908A
Authority
CN
China
Prior art keywords
unsubstituted
substituted
compound
alkyl
base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780032658.2A
Other languages
English (en)
Other versions
CN109641908B (zh
Inventor
蒋华良
柳红
耿美玉
郑明月
艾菁
王玉兰
吴小伟
李双杰
彭霞
李淳朴
陈凯先
王宝
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Materia Medica of CAS
Original Assignee
Shanghai Institute of Materia Medica of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Materia Medica of CAS filed Critical Shanghai Institute of Materia Medica of CAS
Priority claimed from PCT/CN2017/085765 external-priority patent/WO2017202343A1/zh
Publication of CN109641908A publication Critical patent/CN109641908A/zh
Application granted granted Critical
Publication of CN109641908B publication Critical patent/CN109641908B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

本发明提供了一种作为FGFR激酶抑制剂的五元杂环并哒嗪酮类化合物及其制备和应用,具体地,本发明提供了一种如下式(I)所示的化合物;其中,各基团的定义如说明书中所述。本发明的化合物具有很好的FGFR激酶抑制活性,可以用于制备一系列治疗FGFR激酶活性相关的疾病的药物。

Description

PCT国内申请,说明书已公开。

Claims (10)

  1. PCT国内申请,权利要求书已公开。
CN201780032658.2A 2016-05-24 2017-05-24 五元杂环并[3,4-d]哒嗪酮类化合物、其制备方法、药物组合物及其应用 Expired - Fee Related CN109641908B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201610353035 2016-05-24
CN2016103530352 2016-05-24
CN201710060243.8A CN107417687A (zh) 2016-05-24 2017-01-24 五元杂环并[3,4‑d]哒嗪酮类化合物、其制备方法、药物组合物及其应用
CN2017100602438 2017-01-24
PCT/CN2017/085765 WO2017202343A1 (zh) 2016-05-24 2017-05-24 五元杂环并[3,4-d]哒嗪酮类化合物、其制备方法、药物组合物及其应用

Publications (2)

Publication Number Publication Date
CN109641908A true CN109641908A (zh) 2019-04-16
CN109641908B CN109641908B (zh) 2021-11-19

Family

ID=60423438

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710060243.8A Pending CN107417687A (zh) 2016-05-24 2017-01-24 五元杂环并[3,4‑d]哒嗪酮类化合物、其制备方法、药物组合物及其应用
CN201780032658.2A Expired - Fee Related CN109641908B (zh) 2016-05-24 2017-05-24 五元杂环并[3,4-d]哒嗪酮类化合物、其制备方法、药物组合物及其应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201710060243.8A Pending CN107417687A (zh) 2016-05-24 2017-01-24 五元杂环并[3,4‑d]哒嗪酮类化合物、其制备方法、药物组合物及其应用

Country Status (5)

Country Link
US (1) US20190135818A1 (zh)
EP (1) EP3470415A4 (zh)
JP (1) JP2019519534A (zh)
CN (2) CN107417687A (zh)
AU (1) AU2017269462A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107417687A (zh) * 2016-05-24 2017-12-01 中国科学院上海药物研究所 五元杂环并[3,4‑d]哒嗪酮类化合物、其制备方法、药物组合物及其应用
WO2022170952A1 (zh) * 2021-02-09 2022-08-18 苏州阿尔脉生物科技有限公司 一种作为sos1抑制剂的多环哒嗪酮类衍生物、其制备方法及用途
CN114957132A (zh) * 2021-02-20 2022-08-30 中国科学院上海药物研究所 含s构型的氨基苯甲酰胺基哒嗪酮类化合物、其制备方法、药物组合物及应用
CN114225051B (zh) * 2021-12-16 2024-05-10 中国人民解放军空军军医大学 一种用于治疗银屑病的药物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016007185A1 (en) * 2014-07-07 2016-01-14 Eternity Bioscience Inc. Aminopyridazinone compounds as protein kinase inhibitors
WO2016112637A1 (zh) * 2015-01-14 2016-07-21 湖北生物医药产业技术研究院有限公司 Btk抑制剂
CN107417687A (zh) * 2016-05-24 2017-12-01 中国科学院上海药物研究所 五元杂环并[3,4‑d]哒嗪酮类化合物、其制备方法、药物组合物及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013042137A1 (en) * 2011-09-19 2013-03-28 Aurigene Discovery Technologies Limited Bicyclic heterocycles as irak4 inhibitors
US9475815B2 (en) * 2012-02-23 2016-10-25 Bayer Intelletual Property Gmbh Substituted benzothienyl-pyrrolotriazines and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016007185A1 (en) * 2014-07-07 2016-01-14 Eternity Bioscience Inc. Aminopyridazinone compounds as protein kinase inhibitors
WO2016112637A1 (zh) * 2015-01-14 2016-07-21 湖北生物医药产业技术研究院有限公司 Btk抑制剂
CN107417687A (zh) * 2016-05-24 2017-12-01 中国科学院上海药物研究所 五元杂环并[3,4‑d]哒嗪酮类化合物、其制备方法、药物组合物及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YUE YU等: "Facile synthesis of cyanofurans via Michaeladdition/cyclization of ene-yne-ketones with trimethylsilyl cyanide", 《CHEMICAL COMMUNICATIONS (CAMBRIDGE, UNITED KINGDOM)》 *

Also Published As

Publication number Publication date
US20190135818A1 (en) 2019-05-09
CN109641908B (zh) 2021-11-19
EP3470415A1 (en) 2019-04-17
CN107417687A (zh) 2017-12-01
JP2019519534A (ja) 2019-07-11
AU2017269462A1 (en) 2019-01-24
EP3470415A4 (en) 2019-05-22

Similar Documents

Publication Publication Date Title
US10435388B2 (en) Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase
JP5188988B2 (ja) ベンゾアゾール誘導体、組成物、及びオーロラキナーゼ阻害剤としての使用方法
JP6445684B2 (ja) Fgfrキナーゼ阻害剤としてのインダゾール系化合物およびその製造と使用
KR101652229B1 (ko) 증식성 질환의 치료를 위한 키나제 저해제로서 유용한 다이하이드로나프타이리딘 및 관련 화합물
DK2947086T3 (en) UNKNOWN CONDENSED PYRIMIDINE COMPOUND OR SALT THEREOF
WO2017202343A1 (zh) 五元杂环并[3,4-d]哒嗪酮类化合物、其制备方法、药物组合物及其应用
JP5205276B2 (ja) 酵素阻害剤
US10781214B2 (en) Kinase inhibitor against wild-type and mutant EGFR
KR20180041757A (ko) 신규한 피라졸로[3,4-d]피리미딘 화합물 또는 그 염
TW200823200A (en) Compounds and compositions as protein kinase inhibitors
KR20090086219A (ko) 이미다조[1,2-b]피리다진 및 피라졸로[1,5-a]피리미딘 유도체 및 단백질 키나제 억제제로서의 이의 용도
JP6263614B2 (ja) ベンゾイミダゾール−2−ピペラジン複素環系化合物、その医薬組成物及びその調製方法と用途
TW202124381A (zh) 咪唑並[4,5-c]喹啉-2-酮化合物及它們在治療癌症中之用途
CN109641908A (zh) 五元杂环并[3,4-d]哒嗪酮类化合物、其制备方法、药物组合物及其应用
US20150126508A1 (en) Pteridine ketone derivative and applications thereof as egfr, blk, and flt3 inhibitor
TWI760005B (zh) 具有大環結構的含氟並雜環衍生物及其用途
WO2017114512A1 (zh) 含氮稠杂环化合物、制备方法、中间体、组合物和应用
WO2021211741A1 (en) Substituted pyridines for the treatment of inflammatory diseases
US20190375714A1 (en) Quinoline compound, preparation method and medical use therefor
WO2018121400A1 (zh) 酰胺及硫代酰胺类衍生物及其制备方法和应用
CN103214481B (zh) 新型咪唑并[1,2-a]吡啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途
CN109896997A (zh) N-酰基苯胺类c-Met激酶抑制剂的制备方法及其用途
US11572359B2 (en) PARP/PI3K double-target inhibit containing pyridopyrimidine structure
AU2018224359B2 (en) 5-(pyrimidin-4-yl)-2-(pyrrolidin-1-yl)nicotinonitrile compounds as IKKE, TBK1 and/or SIK2 kinases inhibitors
KR20200134179A (ko) N을 포함하는 헤테로아릴 유도체 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20211119